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Background: Pharmacogenomics (PGx) as an emerging field, is poised to change
the way we practice medicine and deliver health care by customizing drug therapies
on the basis of each patient’s genetic makeup. A large volume of PGx data including
information among drugs, genes, and single nucleotide polymorphisms (SNPs) has
been accumulated. Normalized and integrated PGx information could facilitate
revelation of hidden relationships among drug treatments, genomic variations, and
phenotype traits to better support drug discovery and next generation of treatment.
Methods: In this study, we generated a normalized and scientific evidence
supported cancer based PGx network (CPN) by integrating cancer related PGx
information from multiple well-known PGx resources including the Pharmacogenomics
Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the
Catalog of Published Genome-Wide Association Studies (GWAS). We successfully
demonstrated the capability of the CPN for drug repurposing by conducting two
case studies.
Conclusions: The CPN established in this study offers comprehensive cancer based
PGx information to support cancer orientated research, especially for drug repurposing.
Keywords: Pharmacogenomics, Cancer, Network, Drug repurposingBackground
In 2003, the US Food and Drug Administration (FDA) recognized the importance of
PGx data for the evaluation of drug safety and efficacy by starting a voluntary data ex-
change program, which requests that pharmaceutical companies submit genomic data
along with their new drug packages. So far, the FDA has documented PGx information
for more than 100 drugs associated with more than 50 genes [1]. Of these drugs, 42
FDA cancer drugs include PGx information in their package inserts. Clearly, cancer
therapy is one of the most intensively studied topics in PGx [2-4], and relevant PGx
data are accumulating quickly. Thus, it is critical to determine how to use and inte-
grate cancer based PGx information effectively, thereby revealing hidden relationships
among drug treatments, genomic variations, and phenotype traits and better support-
ing drug discovery and next generation of treatment. To our knowledge, no integration
efforts have been directed specifically toward cancer based PGx. Suggested Ontology© 2015 Wang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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two existing ontologies for general PGx integration. They provided a first step toward
integrating and representing PGx (and related) knowledge in the web ontology lan-
guage (OWL), a web standard [7]. SO-Pharm contains so many classes and relations to
represent generic PGx information that it is computationally expensive “and leads to
significantly higher complexity for knowledge composition” [5]. It therefore presents
challenges to users “in asserting knowledge or making routine queries” [5]. PO is a
case-driven PGx data integration platform that aims to question-answering. Our study
aims to integrate PGx information by focusing on oncology domain from diverse PGx
resources. In addition, we will not only integrate existing PGx information, but also
add inferred associations, which will support the novel indication detection for used
drugs.
Idiosyncratic information without semantic interoperability and standard-based anno-
tation, however, adds no value to the scientific commons. These idiosyncratic data must
be annotated using standard terms and elements that correspond to the way scientists
might search, integrate, inference, or expand upon the data. In the oncology commu-
nity, the FDA and National Cancer Institute (NCI) attempt to document approved can-
cer drug information in a meaningful way. For instance, cancer drugs can be browsed
by approved date with detailed description from the FDA [8]; they also can be queried/
browsed by specific cancer type from the NCI [9], in which cancer drugs have been
mapped to the NCI Thesaurus [2]. Nevertheless, to our knowledge, there is no data
normalization effort made for cancer based PGx information. Lack of such effort hin-
ders data sharing and further data integration. The CPN constructed in this study has
been highlighted with normalization tags by leveraging the controlled terminologies
and vocabularies.
In this study, we integrated multiple well known PGx resources including the
PharmGKB [1], the FDA Pharmacogenomic Biomarkers in Drug Labeling [10] and the
Catalog of Published Genome-Wide Association Studies [11], and represented terms by
using relevant standards to construct a cancer based PGx network, named CPN
(Cancer based PGx Network). This work was intended to demonstrate the feasibility
of constructing the CPN to support possible drug repurposing candidate identifica-
tion. To illustrate the capability of the CPN for drug repurposing, two case studies
have been performed successfully.Materials
NCI cancer list
National Cancer Institute (NCI) has maintained the alphabet links for information on a
particular type of cancer. In this study, we have manually collected 160 distinct cancer
types through de-duplication including bladder cancer, breast cancer, leukemia, and so
on from NCI by Nov 14, 2013 [12].Pharmacogenomics knowledge base (PharmGKB)
PharmGKB contains genomic, phenotype and clinical information collected from PGx
studies. It provides information regarding variant annotations, drug-centered pathway,
pharmacogenomic summaries, clinical annotations, PGx-based drug-dosing guidelines,
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tracted from a relationship file received from the PharmGKB by May 8, 2013, which
provides associations between two PGx concepts, including drug, gene, disease, SNP
and haplotype. Some examples are shown in Table 1. All fields listed in Table 1 were
extracted and applied in this study.
The detailed information about individual disease, drug and gene terms were ex-
tracted from the corresponding Disease, Drug and Gene files downloaded from the
PharmGKB by November 15, 2013 [13].FDA Pharmacogenomic biomarkers in drug labeling
The US Food and Drug Administration (FDA) provides a table of biomarkers for some
FDA-approved drugs. The table contains “Therapeutic areas” field indicating the treat-
ment intention of the drugs, such as “Oncology”, “Psychiatry”, etc., as well as the
“HUGO Symbol” field representing associated genes. In this study we extracted these
two fields that are “Oncology” related. The table was downloaded by Dec 3, 2013 [8].Catalog of published genome-wide association studies
NIH provides a Catalog of Published Genome-Wide Association Studies (GWAS),
which has identified single nucleotide polymorphisms (SNPs) and reported genes for
major disease traits. We extracted cancers and related genes and SNPs from the
“Disease/Trait”, the “Reported Gene(s)” and “SNPs” fields respectively. The Catalog
was downloaded by Dec 3, 2013 [11].National Center for Biomedical Ontology (NCBO)
The NCBO provides an ontology-based web service that can annotate public datasets
with biomedical ontology concepts [14]. The reasons to select the NCBO bioportal for
the normalization task in this study are 1) our previous work [15] has shown the
capability of NCBO to support PGx data normalization, 2) its convenience of online
access and its large scale of more than 400 ontologies [16] beyond other tools such
as Metamap. We used the NCBO Bioportal REST service [17] to access biomedical
ontologies. In this study, we utilized this service to normalize disease and drug terms
with Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) [18]
and RxNorm [19].Table 1 Examples of PGx associations extracted from the PharmGKB
Entity1_id Entity1_ name Entity1_ type Entity2_id Entity2_ name Entity2_ type PMIDs
PA443512 Urinary bladder
neoplasms










Disease PA27093 CYP1A2 Gene 18496682;
19581389
PA27093 CYP1A2 Gene PA450688 olanzapine Drug 19636338;
21519338
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SemMedDB is a repository of semantic predications (subject-predicate-object triples) ex-
tracted from the entire set of PubMed citations with SemRep. The subject and object pair
corresponds to UMLS Metathesaurus concepts, and the predicate to a relation type in an
extended version of the semantic network. SemMedDB contains eight tables and is updated
at regular intervals. We downloaded the latest PREDICATION_AGGREGATE table with
ending date of MAR 31 2014 [20]. In this study, we identified scientific evidence, PubMed
IDs from SemMedDB for PGx associations present in the CPN.Methods
In this study, we designed an approach including four steps to generate the CPN: 1) can-
cer based PGx association identification, 2) cancer based PGx concept normalization, 3)
scientific evidence identification, and 4) the CPN generation. In the first step, we identi-
fied cancer based PGx associations from the PharmGKB, the GWAS Catalog and the
FDA Biomarker table. Then we mapped cancer based PGx concepts to standard vocabu-
laries, for instance, drugs to RxNorm, diseases to SNOMED-CT, genes to HUGO gene
symbol and so on. Once the PGx associations were normalized and scientific evidences
were identified from SemMedDB, we built the CPN. Figure 1 presents the architecture
developed for the CPN construction. More details about each step and case studies will
be described in the following sections.Cancer based PGx association identification
To extract cancer based PGx associations, we first manually collected 160 distinct NCI
cancer terms called as seeds from the NCI Cancer List. Then we performed an iterative
search to identify PGx associations related to these seeds from PharmGKB. This search
was not terminated until fourth-degree concepts that are four nodes away from theFigure 1 The architecture of the approach being used for the CPN construction.
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first-degree concepts that are directly connected to the seeds, then we retrieved
second-degree concepts that are neighbors of the first degree concepts, followed by
locating third-degree concepts that are neighbors of the second-degree concepts,
then the fourth–degree concepts. We iteratively extracted associations related to
these seeds from fields listed in Table 1. For instance, beginning with the seed “Urinary
Bladder Neoplasms”, we can iteratively find associations, including “rs762551” - “Urinary
Bladder Neoplasms”, “Arthritis, Rheumatoid” - “rs762551”, “CYP1A2” - “Arthritis,
Rheumatoid”, and “Olanzapine” - “CYP1A2”, which are shown in Table 1. These pairs are
as building blocks being used for constructing the CPN. Besides drug, disease and gene,
we also extracted haplotype and SNP information that exist in the PharmGKB relation-
ship file. To reflect an assumption that concepts with shorter distance to the seeds might
have stronger associations with these seeds, we assigned different weight scores to PGx
concepts based on their degrees. The first-degree concept was conferred with a higher
weight score of “4”, then the second degree with “3”, the third degree with “2” and the
fourth degree with “1”.
Additional PGx information available from the GWAS Catalog and the FDA bio-
marker table has also been extracted. We manually identified the seeds in the GWAS
Catalog based on the NCI cancer terms. We then extracted the PGx associations re-
lated to the seeds from fields of “Disease/Trait”, “Reported Gene(s)” and “SNPs” in
the GWAS Catalog. It is worthy to note that we did not perform an iterative search to
find indirect associations from GWAS Catalog, as we were only interested in the associa-
tions extracted from this Catalog co-occurring in the PharmGKB. In parallel, we extracted
PGx pairs between “Oncology” drugs and associated genes from the FDA biomarker
table.Cancer based PGx association normalization
We normalized disease terms by SNOMED-CT [18], drugs by RxNorm [19], genes by
the Human Genome Organization (HUGO) [21] gene symbols, SNP by the National
Center for Biotechnology Information [22] reference SNP ID number (rsID). Genes,
SNPs, haplotypes derived from the three resources have already been represented in
standard forms. Therefore, no additional normalization process has been performed ac-
cordingly. In this study, we primarily focused on the normalization for drug and disease
terms.
A. Disease term normalization
PharmGKB provides manual annotations for disease terms with normalized vocabular-
ies, including SNOMED-CT [18], Medical Subject Headings (MeSH) [23], Unified
Medical Language System (UMLS) [24], etc., which are available in the downloadable
Disease file. However, the mapping to SNOMED-CT is incomplete. There is no
SNOMED-CT code available for cancer terms in GWAS catalog. Thus, we normalized
disease terms that are without SNOMED-CT codes by employing the NCBO Bioportal
REST service [17] programmatically. A Java program has been written to automatically
invoke this REST service and parse the XML file as output to retrieve SNOMED-CT
codes. Note that we specified “isexactmatch = 1” as one of the input parameters when
executing the NCBO REST service. That is to say, the mapped SNOMED-CT terms are
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validate the mapping performance afterwards. We manually checked and mapped the
unmapped disease terms to SNOMED-CT with their synonyms.
B. Drug term normalization
The same mapping strategy has been applied to drug terms, 1) we reused the normal-
ized terms from the PharmGKB; 2) the NCBO Bioportal REST service was invoked to
retrieve RxNorm Concept Unique Identifiers (RxCUIs) for those PharmGKB drugs and
the drugs from the FDA biomarker table (no drug information in the GWAS catalog)
that are without RxCUIs; 3) manual annotation was performed for unmapped drugs.
Two authors (LW, QZ) had reviewed and evaluated the mappings, and finalized the
mapping lists for further CPN construction.Scientific evidence identification
To insert scientific evidence, namely, published studies to support PGx associations
presented in the CPN, we searched for SemMedDB accordingly. Besides PubMed refer-
ences existing in the PharmGKB, we searched for PGx associations from the GWAS
catalog and the FDA biomarker table against SemMedDB.Cancer based PGx network construction
Once the cancer based PGx associations were identified, we linked concepts occurring
across three resources to construct the CPN. In the CPN, the nodes correspond to indi-
vidual cancer based PGx concepts including drug, gene, disease, SNP and haplotype.
The edges correspond to PGx associations. Table 2 shows the types of PGx associations
contained in the CPN.Results
Cancer based PGx association identification
A. PharmGKB
Total 38 distinct seeds have been identified from the PharmGKB. Accordingly, we have
extracted 2,964 concepts that are associated with these seeds, corresponding to 13,221
PGx pairs. Among these pairs, there are 402 drugs, 205 diseases, 825 genes, 1333 SNPs
and 199 haplotypes.
Table 3 shows results of PGx associations extracted from the PharmGKB. For ex-
ample, there are 38 seeds (cancer terms) associated with 393 Disease-Gene pairs, 37
Disease-Haplotype pairs and 530 Disease-SNP pairs. The numbers shown in Table 3




















































Seeds 38 393 37 530 0 0 0 0 0
1 605 1018 50 1155 1827 77 1607 0 195
2 735 1700 278 2483 2972 974 3716 1 944
3 2646 1705 277 2492 2965 974 3710 1 982
4 1196 0 0 0 0 0 0 0 0
Total 2964 1723 277 2500 3012 974 3718 1 1016
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We manually identified 42 cancer drugs from the FDA biomarker table. As some of
drugs are associated with multiple genes, total 55 drug and gene pairs corresponding to
44 genes were extracted.
We extracted 31 cancer terms from the GWAS catalog, of which there are 2455 PGx
pairs corresponding to 720 genes and 598 SNPs.Cancer based PGx association normalization
Among 402 drugs extracted from the PharmGKB in this study, RxCUIs are available
for 323 drugs. For the rest of 79 drugs without RxCUIs, 53 were mapped to RxNorm
by invoking the NCBO REST service programmatically. For 205 PharmGKB disease
terms being used in this study, SNOMED-CT codes are available for 186 disease terms.
Another 10 diseases were mapped to SNOMED-CT by invoking the NCBO REST ser-
vice programmatically. Of 42 drugs from the FDA biomarker table, 41 were mapped to
RxNorm by using NCBO REST service. Of 31 cancer terms identified from the GWAS
Catalog, 29 were mapped to SNOMED-CT by the NCBO REST service. Furthermore,
we manually mapped 5 drugs and 8 diseases to the standards accordingly.
In summary, 394 out of 416 (94.7%) unique drug concepts have been mapped to
RxNorm, and 215 out of 218 (98.6%) unique disease concepts been mapped to
SNOMED-CT. Reasons for the failed mapping will be discussed in the discussion section.Scientific evidence identification
Besides PubMed references existing in the PharmGKB, 19 PGx pairs corresponding to
16 drugs and 13 genes in the FDA biomarker table were retrieved to be with PubMed
IDs and 6 predicates including “COEXISTS_WITH”, “compared_with”, “higher_than”,
“INHIBITS”, “INTERACTS_WITH” and “USES” from the SemMedDB. Meanwhile, total
253 PGx pairs (24 diseases and 89 genes) from the GWAS Catalog were retrieved to be
with PubMed IDs and 8 predicates including “AFFECTS”, “ASSOCIATED_WITH”,
“AUGMENTS”, “CAUSES”, “NEG_ASSOCIATED_WITH”, “NEG_PART_OF”, “PART_OF”
and “PREDISPOSES” from the SemMedDB.Cancer based PGx network (CPN)
The CPN contains 4,342 distinct nodes and 15,600 pairs in total. We explored Cytos-
cape [25] to visualize the CPN. A sub-network extracted from the CPN specifically for
“urinary bladder cancer” is shown at the left lower corner of Figure 1.
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The CPN provides comprehensive PGx information to support advanced cancer rele-
vant research. Specifically, we can identify possible drug repurposing candidates from
the CPN by utilizing network analysis approaches. The below two case studies illustrate
the capability of the CPN for drug repurposing. It is worthy to note that we manually
identified relevant literatures to further evaluate the findings produced in these two
case studies and the feasibility of this present study for drug repurposing. However, the
ultimate goal of this study is to identify novel drug repurposing candidates that are
without supportive scientific evidences, and they will attract interests of chemists and/
or biologists for further experimental evaluation.
A. Case study 1
Paclitaxel is used to treat Kaposi’s sarcoma, as well as the lung, ovarian, and breast can-
cer, as documented in the “Indications & Usage” section of the structured product label
[26]. In this case study, we were interested in revealing the new indications of Paclitaxel
from the CPN. We searched the CPN for Paclitaxel with RxCUI = “56946” and identi-
fied relevant disease concepts that are at most 3 nodes away from the Paclitaxel. More
specifically, we searched for direct and indirect disease associations that are relevant to
Paclitaxel and those disease nodes are at most 3 nodes away from Paclitaxel. In total,
there are 70 concepts directly associated with Paclitaxel, 399 concepts including 110
disease concepts that are two nodes away from Paclitaxel, and 1689 concepts including
110 disease concepts that are three nodes away from Paclitaxel. To further evaluate
and determine the possible novel indications and the appropriateness of our approach,
we manually sought scientific evidences from PubMed literatures to support new indi-
cations inferred from the CPN. As a result, 20% newly identified indications including
Alzheimer Disease, Asthenia, Leukemia, etc. for Paclitaxel are supported by published
studies. To detail our approach, Alzheimer Disease as one novel indication identified
for Paclitaxel from the CPN is shown as below.
“MTHFR” and “rs1801133” are the two direct nodes connected to Paclitaxel, sub-
sequently “Alzheimer Disease” with SNOMED-CT code, “26929004” has been iden-
tified via the above two nodes, as shown in Figure 2. rs1801133 is encoding a
variant in the MTHFR gene, which encodes an enzyme involved in folate metabol-
ism [27]. Then associations of Paclitaxel-MTHFR-“Alzheimer Disease”, can be fur-
ther validated by literatures as follows, 1) Paclitaxel enhanced the inhibition of
MTHFR by antisense or small molecules, which decreases tumor growth [28]; 2)
The severity and biochemical risk factors of Alzheimer’s disease may be influenced
by the MTHFR 677 T allele in an Egyptian population [29] and the association be-
tween MTHFR A1298C polymorphisms as a possible risk factor and Alzheimer’s
disease was verified [30].
By analyzing the CPN, Paclitaxel is related to “Alzheimer Disease” via gene MTHFR
and SNP “rs1801133”. In addition, evidences are mounting in the literature that Alzheimer
disease may be a new indication of the cancer drug Paclitaxel, for example Paclitaxel
may rescue neurons from undergoing hallmark tau-induced Alzheimer disease cell
pathologies [31] and Paclitaxel has the potential to treat Alzheimer disease [32]. That
is to say,Paclitaxel may be a potential drug repurposing candidate for the treatment of
Alzheimer Disease.
Figure 2 A sub-network of Paclitaxel taken from the CPN. Blue solid lines indicate the direct association
existed in the CPN, while the red dotted line indicates the indirect inference applied in this case study.
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Capecitabine is originally indicated for the treatment of breast cancer and colorectal
cancer as stated in the drug label [33]. In this case study, we aimed to seek alternative
indications for Capecitabine. We searched for Capecitabine with RxCUI “194000” from
the CPN to identify novel indications. In total, there are 120 disease nodes that are at
most 3 nodes away from Capecitabine. Of these 120 diseases, 12 possible novel indica-
tions including Hyperbilirubinemia, Mesothelioma, Bladder Neoplasm, etc. associated
with Capecitabine are supported by published studies. The following example illustrates
the identification process of the new indication, bladder neoplasm for Capecitabine.
From the CPN 50 directly relevant nodes have been retrieved for Capecitabine in-
cluding the gene CYP1A1, from which “Urinary Bladder Neoplasms” have been identi-
fied subsequently. A sub-network of Capecitabine visualized by Cytoscape in the CPN
is shown at the right lower corner in Figure 1, where the edges in red indicate all asso-
ciations with Capecitabine, and the green edges indicate DPYD and C18orf56 are link-
ing to Capecitabine respectively. The zoomed out network is shown in Figure 3. The
association between “Urinary Bladder Neoplasms” and “Capecitabine” could be inferred
through multiple paths as shown in Figure 3. Among all paths between these two, the
shortest path is Capecitabine-CYP1A1-Urinary Bladder Neoplasms, of which the asso-
ciation could be proved by literatures: (1) “CYP1A1 rs1048943 A > G (Ile462Val) poly-
morphism is a potential prognostic marker for survival outcome after docetaxel plus
capecitabine chemotherapy” [34]; (2) active CYP1A1 and CYP1B1 overexpression is re-
vealed in bladder cancer [35]; (3) the combination of Capecitabine and radiation ther-
apy offers a promising treatment option for bladder cancer patients who are not
candidates for surgery or cisplatin-based chemotherapy [36]; (4) a patient with meta-
static bladder cancer responded well to second-line capecitabine with a clinically mean-
ingful progression-free survival [37]. Through this validation chain, the inference that
the breast and colorectal cancer drug, “Capecitabine” might be used for urinary bladder
Figure 3 A sub-network of Capecitabine taken from the CPN. Blue solid lines indicate the direct association
existed in the CPN, while the red dotted line indicates the indirect inference applied in this case study.
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Capecitabine via the network-based analysis of the CPN.
Discussion
Benefits gained from the CPN
A. Supporting further data integration
Data integration is essential in the big data era. It is important to aggregate different
pieces of data from different areas to solve fundamental scientific questions. Particu-
larly, in this study we have integrated data from various PGx data resources and built a
cancer based PGx data repository. The concepts (nodes) included in the CPN were nor-
malized with multiple standard biomedical terminologies and domain standards. Once
the normalization task is accomplished, more relevant data can be deposited and inte-
grated into the CPN, such as Electronic Medical Records (EHRs), DrugBank [38] and
KEGG [39]. Besides a majority portion (99.4%) of the concepts has been normalized,
about 0.6% of concepts was failed to be normalized. The reason of failure is in two folds.
First, chemical IUPAC names were used as drug names in the PharmGKB, which were
not included in RxNorm, e.g., “1-methyloxy-4-sulfone-benzene”. Second, drug class
names were being used, such as “Analgesics and Anesthetics” and “Antiinflammatory and
Antirheumatic Products”. In terms of diseases, the names were either presented too
broadly, such as, “Substance-Related Disorders” or too narrowly, such as “Therapy Related
Acute Myeloid Leukemia”, so that they cannot be mapped to SNOMED-CT.
B. Supporting oncology based drug discovery
PGx data including the detailed information for drugs, diseases, genes, SNPs, etc., has
been regarded as a basis for individualized medicine. While generic PGx data could be
obtained publicly, drug, disease, gene, SNP and haplotype resources have not, as yet,
been well-integrated to support the oncology based drug discovery. With various asso-
ciation types including Disease-Gene, Drug-Gene, etc. as shown in Table 2, the CPN
can serve as a highly relevant cancer knowledge base and a valuable platform for oncol-
ogy based research on drug repurposing. Thus, it would result in the shortening of the
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capability of the CPN. Additionally two advantages inherent in the CPN will strengthen
its application in drug repurposing, including: 1) the CPN contains both direct and in-
direct cancer based PGx associations, thus, more drug candidates can be identified via
automated inference; 2) a majority of concepts contained in the CPN are normalized
with standard vocabularies, which enables further integration with other relevant re-
sources to support more novel indication identifications.
Limitation and future study
A. Path ranking
The current version of the CPN includes cancer based PGx information extracted from
three major PGx resources. Although only 38 cancer terms have been found in the
PharmGKB, 42 cancer drugs identified from the FDA biomarker table, and 31 cancer
terms found from the GWAS catalog, the total number of nodes and edges of the CPN
is 19,942, as we included all associations up to four nodes away from the cancer seeds.
In this study, we focused on the CPN construction and the demonstration of the cap-
ability of the CPN. Path ranking to output a ranked list of paths that are associated
with specific concepts from the CPN was out of scope of this study. However, when we
conducted case studies, in order to filter out the most significant paths based on the
queries, some initial ranking rules have been applied. For example, weight scores ac-
cording to the degrees of concepts, path length, and VIP pairs from the PharmGKB
have been applied for path ranking. In the future study, we will incorporate these rules
with other ranking methods, such as PageRank [40], and genetic association p-values
derived from GWAS [11], to output the most correlated paths for a particular query.
B. Disambiguating drug-disease association
Detailed information on specifying drug and disease association is critical for drug re-
purposing, as we have to determine whether this drug is used to treat this disease or
this drug may cause such a disease as an adverse drug event. Consequently, the novel
indication may be identified for this drug for further evaluation. In this study, all drug
and disease associations were directly extracted from the original resources, no add-
itional step has been applied to disambiguate such associations. In our previous study,
we have employed NDF-RT and SPLs to annotate drug and disease relationships in the
PharmGKB [41]. We will apply the annotation results [41] along with the existing an-
notations from NDF-RT, ADEpedia [42], LinkedSPLs [43] into the future study, insert-
ing a particular tag for differentiating indications and adverse drug events.
C. Scientific evidence identification
The established CPN is supported by published studies, PubMed references extracted
from SemMedDB. However, not all CPN associations have been assigned with pubmed
IDs. 36 PGx pairs from the FDA biomarker table and 2202 PGx pairs from the GWAS
Catalog were not mapped. SemRep, a rule-based semantic interpreter extracting predi-
cates in Pubmed references being applied by SemMedDB, has shown its precision for
gene-disease relations as 76% [44]; the precision and recall for pharmacogenomics as
73% and 55% [45] respectively. Thus we doubt that all association presented in this
study have been extracted and included in SemMedDB. On the other hand, we performed
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mappings. In the future, we would use machine learning and natural language processing
(NLP) to identify more associations on the basis of existing PubMed references.
D. Data integration
In this preliminary study, we extracted and integrated three well-known PGx resources
to build the CPN. To make the CPN more informative, we will extract further cancer
based PGx information from other public PGx resources, such as DrugBank, KEGG,
etc., them and integrate into the CPN. Meanwhile, we will identify PGx associations
from pathways, and apply NLP [46] tools and algorithms to automatically extract such
associations from literatures periodically. The ultimate goal will be leveraging semantic
web technologies (SWT) [47] to present such comprehensive cancer based PGx infor-
mation in RDF [48] or OWL [49], which can support automated inference for drug
repurposing.
Conclusions
In this study we have integrated three existing PGx resources into the CPN, which is
supported by published studies, PubMed references extracted from SemMedDB. The
established CPN offers comprehensive cancer based PGx information to support cancer
orientated research, especially for drug repurposing, the potential of which has been
successfully demonstrated by case studies.
Abbreviations
PGx: Pharmacogenomics; SNPs: Single nucleotide polymorphisms; CPN: Cancer based PGx network;
PharmGKB: Pharmacogenomics knowledge base; GWAS: Genome-wide association studies; OWL: Web ontology
language; NCI: National Cancer Institute; SNOMED-CT: Systematized nomenclature of medicine-clinical terms;
NCBO: National Center for Biomedical Ontology; MeSH: Medical subject headings; UMLS: Unified medical language
system; rsID: Reference SNP ID number.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
LW carried out the experiment and data analysis supervised by QZ, and drafted the manuscript; QZ conceived this
study, assembled and revised the manuscript; HL helped on data analysis. CGC: reviewed manuscript and provided
feedback and suggestions. All contributed to the intellectual evolution of this project. All authors have read and
approved the final manuscript.
Acknowledgements
This work was supported by the Pharmacogenomic Research Network (NIH/NIGMS-U19 GM61388).
Author details
1Department of Medical Informatics, School of Public Health, Jilin University, Changchun 130021, China. 2Department
of Health Science Research, Mayo Clinic, Rochester, MN 55901, USA. 3Division of General Internal Medicine, Johns
Hopkins University, Baltimore, MD 21287, USA. 4Department of Information Systems, University of Maryland Baltimore
County, Baltimore, MD 21055, USA.
Received: 5 August 2014 Accepted: 12 February 2015
References
1. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB, et al. PharmGKB: the pharmacogenetics
knowledge base. Nucleic Acids Res. 2002;30(1):163–5.
2. Fu B, Brennan R, O’Sullivan D. A configurable translation-based cross-lingual ontology mapping system to adjust
mapping outcomes. Web Semant Sci Serv Agents World Wide Web. 2012;15:15–36.
3. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene
fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–4.
4. Kreso A, O’Brien CA, van Galen P, Gan F, Notta OI, Brown AM, et al. Variable clonal repopulation dynamics
influence chemotherapy response in colorectal cancer. Science. 2013;339(6119):543–8.
Wang et al. BioData Mining  (2015) 8:9 Page 13 of 145. Coulet A, Smaïl-Tabbone M, Napoli A, Devignes MD. Suggested ontology for pharmacogenomics (SO-Pharm):
modular construction and preliminary testing. On the Move to Meaningful Internet Systems 2006: OTM 2006
Workshops. Springer Berlin Heidelberg, 2006: 648-657.
6. Dumontier M, Villanueva-Rosales N. Towards pharmacogenomics knowledge discovery with the semantic web.
Brief Bioinform. 2009;10(2):153–63.
7. Antoniou G, Van Harmelen F. Web ontology language: Owl. Handbook on ontologies. Springer Berlin Heidelberg,
2004: 67-92.
8. FDA table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/drugs/scienceresearch/
researchareas/pharmacogenetics/ucm083378.htm. Accessed Jan 14, 2014.
9. Kumar SK, Harding JA. Ontology mapping using description logic and bridging axioms. Comput Ind. 2013;64(1):19–28.
10. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker
information in drug labels approved by the United States food and drug administration: prevalence of related
drug use. Pharmacotherapy. 2008;28(8):992–8.
11. Hindorff LA MJEBI, Morales J (European Bioinformatics Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA.
A catalog of published genome-wide association studies. www.genome.gov/gwastudies. Accessed Jan 14, 2014.
12. National Cancer Institute. http://www.cancer.gov/cancertopics/types/alphalist. Accessed Jan 14, 2014.
13. The pharmcogenomics knowledgebase. http://www.pharmgkb.org/. Accessed Jan 14, 2014.
14. Whetzel PL, Noy NF, Shah NH, Alexander PR, Nyulas C, Tudorache T, et al. BioPortal: enhanced functionality via
new web services from the National Center for Biomedical Ontology to access and use ontologies in software
applications. Nucleic Acids Res. 2011;39 suppl 2:W541–5.
15. Zhu Q, Freimuth RR, Lian Z, Bauer S, Pathak J, Tao C, et al. Harmonization and semantic annotation of data
dictionaries from the pharmacogenomics research network: a case study. J Biomed Inform. 2013;46(2):286–93.
16. Whetzel PL, NCBO Team. NCBO Technology: Powering semantically aware applications. J Biomedical Semantics.
2013;4(S-1):S8.
17. National center for biomedical ontology rest service. http://data.bioontology.org/documentation. Accessed Jan.
14, 2014.
18. Bos L. SNOMED-CT: the advanced terminology and coding system for eHealth. Med Care Compunetics 3.
2006;121:279.
19. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am
Med Inform Assoc. 2011;18(4):441–8.
20. Kilicoglu H, Fiszman M, Rodriguez A, Shin D, Ripple A, Rindflesch TC. Semantic MEDLINE: a web application for
managing the results of PubMed Searches. Proceedings of the third international symposium for semantic mining
in biomedicine. 2008: 69-76.
21. Gardiner K. Human genome organization. Curr Opin Genet Dev. 1995;5(3):315–22.
22. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, et al. Database resources of the national
center for biotechnology information. Nucleic Acids Res. 2011;39 suppl 1:D38–51.
23. Coletti MH, Bleich HL. Medical subject headings used to search the biomedical literature. J Am Med Inform Assoc.
2001;8(4):317–23.
24. Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids
Res. 2004;32 suppl 1:D267–70.
25. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to Cytoscape plugins. Nat
Methods. 2012;9(11):1069–76.
26. Drug label of paclitaxel in dailymed. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid–9ffd3e34–537f–4f65-
b00e–57c25bab3b01#nlm34067–9. Accessed Feb 20, 2014.
27. Yu L, Chen J. Association of MHTFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an
update meta-analysis based on 51 research studies. Diagn Pathol. 2012;7(1):171.
28. Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell
survival in vitro and tumor growth in vivo. Clin Cancer Res. 2005;11(5):2047–52.
29. Elhawary NA, Hewedi D, Arab A, Teama S, Shaibah H, Tayeb MT, et al. The MTHFR 677 T allele may influence the
severity and biochemical risk factors of Alzheimer’s disease in an Egyptian population. Dis Markers. 2013;35(5):439–46.
30. Mansouri L, Fekih-Mrissa N, Klai S, Mansour M, Gritli N, Mrissa R. Association of methylenetetrahydrofolate reductase
polymorphisms with susceptibility to Alzheimer’s disease. Clin Neurol Neurosurg. 2013;115(9):1693–6.
31. Shemesh OA, Spira ME. Rescue of neurons from undergoing hallmark tau-induced Alzheimer’s disease cell pathologies
by the antimitotic drug paclitaxel. Neurobiol Dis. 2011;43(1):163–75.
32. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau
sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.
Proc Natl Acad Sci U S A. 2005;102(1):227–31.
33. Drug label of capecitabine in dailymed. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1de8bba–3b1d–
4c9d-ab8a–32d2c05e67c8. Accessed Jan 14, 2014.
34. Dong N, Yu J, Wang C, Zheng X, Wang Z, Di L, et al. Pharmacogenetic assessment of clinical outcome in patients
with metastatic breast cancer treated with docetaxel plus capecitabine. J Cancer Res Clin Oncol. 2012;138(7):1197–203.
35. Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, et al. Expression Profile of
CYP1A1 and cyp1b1 enzymes in colon and bladder tumors. PLoS One. 2013;8(12):e82487.
36. Patel B, Forman J, Fontana J, Frazier A, Pontes E, Vaishampayan U. A single institution experience with concurrent
capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol
Phys. 2005;62(5):1332–8.
37. Michels J, Barbour S, Cavers D, Chi KN. Metastatic signet-ring cell cancer of the bladder responding to
chemotherapy with capecitabine: case report and review of literature. Can Urol Assoc J. 2010;4(2):E55–57.
38. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for
in silico drug discovery and exploration. Nucleic Acids Res. 2006;34 suppl 1:D668–72.
39. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
Wang et al. BioData Mining  (2015) 8:9 Page 14 of 1440. Page L, Brin S, Motwani R, Winograd T. The PageRank citation ranking: bringing order to the web. 1999.
41. Zhu Q, Freimuth RR, Pathak J, Durski MJ, Chute CG. Disambiguation of PharmGKB drug–disease relations with
NDF-RT and SPL. J Biomed Inform. 2013;46(4):690–6.
42. Jiang G, Solbrig HR, Chute CG. ADEpedia: a scalable and standardized knowledge base of Adverse Drug Events
using semantic web technology. AMIA annual symposium proceedings. Am Med Inform Assoc. 2011;2011:607–16.
43. Hassanzadeh O, Zhu Q, Freimuth R, Boyce R. Extending the “Web of Drug Identity” with Knowledge Extracted
from United States Product Labels. AMIA Summits Transl Sci Proc. 2013;2013:64–8.
44. Rindflesch TC, Libbus B, Hristovski D, Aronson AR, Kilicoglu H. Semantic relations asserting the etiology of genetic
diseases. AMIA Annual Symposium Proceedings. Am Med Inform Assoc. 2003;2003:554–8.
45. Ahlers CB, Fiszman M, Demner-Fushman D, Lang FM, Rindflesch TC. Extracting semantic predications from Medline citations
for pharmacogenomics. Pac Symp Biocomput. 2007;12:209–20.
46. Chowdhury GG. Natural language processing. Annu Rev Info Sci Technol. 2003;37(1):51–89.
47. Berners-Lee T, Hendler J, Lassila O. The semantic web. Sci Am. 2001;284(5):28–37.
48. McBride B. The resource description framework (RDF) and its vocabulary description language RDFS. Handbook
on ontologies. Springer Berlin Heidelberg, 2004: 51-65.
49. McGuinness DL, Van Harmelen F. OWL web ontology language overview. W3C Recomm. 2004;10(10):2004. http://www.w3.
org/TR/owl-features/.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
